US Stem Cell Inc
OTC:USRM
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Anabuki Kosan Inc
TSE:8928
|
JP |
US Stem Cell Inc
Inventory
US Stem Cell Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
US Stem Cell Inc
OTC:USRM
|
Inventory
$1k
|
CAGR 3-Years
-50%
|
CAGR 5-Years
-57%
|
CAGR 10-Years
-34%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Inventory
$5B
|
CAGR 3-Years
11%
|
CAGR 5-Years
8%
|
CAGR 10-Years
11%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Inventory
$1.8B
|
CAGR 3-Years
6%
|
CAGR 5-Years
1%
|
CAGR 10-Years
-1%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Inventory
$6.2B
|
CAGR 3-Years
8%
|
CAGR 5-Years
10%
|
CAGR 10-Years
10%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Inventory
$1.7B
|
CAGR 3-Years
54%
|
CAGR 5-Years
43%
|
CAGR 10-Years
40%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Inventory
$2.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
5%
|
CAGR 10-Years
26%
|
|
US Stem Cell Inc
Glance View
U.S.Stem Cell, Inc. is a biotechnology company, which focuses on the discovery, development, and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of chronic and acute heart damage. The company is headquartered in Sunrise, Florida. The company went IPO on 2008-02-19. Stem Cell, Inc. is a biotechnology company that is focused on the discovery, development and subject to regulatory approval, commercialization of autologous cell therapies for the treatment of disease and injury. Its MyoCell and MyoCell SDF-1 product candidates are autologous muscle-derived cellular therapies designed to populate regions of scar tissue within a patient’s heart with new living cells for the purpose of improving cardiac function in chronic heart failure patients. Its Adipocell product is a cell therapy with a range of treatment applications using autologous adipose cells. The firm's business includes the development of cell therapy products, distribution of regenerative medicine products, as well as physician and patient-based regenerative medicine/cell therapy training services. The firm operates through its US Stem Cell Training, Inc. (SCT) and Vet biologics (VBI) divisions.
See Also
What is US Stem Cell Inc's Inventory?
Inventory
1k
USD
Based on the financial report for Dec 31, 2022, US Stem Cell Inc's Inventory amounts to 1k USD.
What is US Stem Cell Inc's Inventory growth rate?
Inventory CAGR 10Y
-34%
Over the last year, the Inventory growth was 150%. The average annual Inventory growth rates for US Stem Cell Inc have been -50% over the past three years , -57% over the past five years , and -34% over the past ten years .
